- Home
- DSGN vs GLSI Comparison
DSGN vs GLSI Comparison
Compare DSGN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- GLSI
- Stock Information
- Founded
- DSGN 2017
- GLSI 2006
- Country
- DSGN United States
- GLSI United States
- Employees
- DSGN N/A
- GLSI N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- GLSI Health Care
- Exchange
- DSGN Nasdaq
- GLSI Nasdaq
- Market Cap
- DSGN 208.9M
- GLSI 121.3M
- IPO Year
- DSGN 2021
- GLSI 2020
- Fundamental
- Price
- DSGN $4.00
- GLSI $10.84
- Analyst Decision
- DSGN Hold
- GLSI Strong Buy
- Analyst Count
- DSGN 1
- GLSI 1
- Target Price
- DSGN $4.00
- GLSI $39.00
- AVG Volume (30 Days)
- DSGN 101.9K
- GLSI 42.4K
- Earning Date
- DSGN 08-04-2025
- GLSI 08-13-2025
- Dividend Yield
- DSGN N/A
- GLSI N/A
- EPS Growth
- DSGN N/A
- GLSI N/A
- EPS
- DSGN N/A
- GLSI N/A
- Revenue
- DSGN N/A
- GLSI N/A
- Revenue This Year
- DSGN N/A
- GLSI N/A
- Revenue Next Year
- DSGN N/A
- GLSI N/A
- P/E Ratio
- DSGN N/A
- GLSI N/A
- Revenue Growth
- DSGN N/A
- GLSI N/A
- 52 Week Low
- DSGN $2.60
- GLSI $8.06
- 52 Week High
- DSGN $7.77
- GLSI $17.00
- Technical
- Relative Strength Index (RSI)
- DSGN 55.03
- GLSI 68.28
- Support Level
- DSGN $3.52
- GLSI $8.97
- Resistance Level
- DSGN $4.21
- GLSI $10.32
- Average True Range (ATR)
- DSGN 0.28
- GLSI 0.46
- MACD
- DSGN 0.03
- GLSI 0.23
- Stochastic Oscillator
- DSGN 77.27
- GLSI 81.13
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.